This is a pilot study of thrombolytic therapy in patients with ischemic stroke who present with stroke symptoms upon awakening.
Patients with ischemic stroke are currently only eligible for the treatment with intravenous thrombolysis if the stroke is diagnosed within 4.5 hours from known onset of symptoms.
Many patients awaken with stroke and are excluded from this therapy, following current guidelines.
Patients who suffer from a stroke just before or after waking up may be candidates for thrombolysis and our study will use advanced neuroimaging to select those patients.
- Alteplase (tPA) Drug
Other Names: Activase®; rt-PA; t-PA; tPA Intervention Desc: 0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour. ARM 1: Kind: Experimental Label: Alteplase Description: Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
- Allocation: Non-Randomized
- Masking: Open Label
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Single Group Assignment
|Type||Measure||Time Frame||Safety Issue|
|Primary||Symptomatic Intracranial Hemorrhage||0-72 hours||Yes|
|Secondary||Modified Rankin Scale||90 days||No|
|Secondary||National Institutes of Health Stroke Scale (NIHSS)||24 hours||No|